Dow Down1.60% Nasdaq Down0.39%

Cerus Corporation (CERS)

5.20 Down 0.46(8.13%) 4:00PM EST
|After Hours : 5.20 0.00 (0.00%) 6:20PM EST
ProfileGet Profile for:
Cerus Corporation
2550 Stanwell Drive
Concord, CA 94520
United States - Map
Phone: 925-288-6000

Index Membership:N/A
Full Time Employees:144

Business Summary 

Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Cerus Corporation

Corporate Governance 
Cerus Corporation’s ISS Governance QuickScore as of Feb 1, 2016 is 10. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 10; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. William M. Greenman , 49
Chief Exec. Officer, Pres and Director
Dr. Laurence M. Corash M.D., 72
Co-Founder, Chief Scientific Officer and Corp. Director
Mr. Kevin D. Green , 44
Chief Financial Officer and VP of Fin.
Ms. Carol M. Moore , 66
Sr. VP of Regulatory Affairs, Quality and Clinical
Mr. Caspar Hogeboom , 57
Pres of Cerus Europe and EEMEA
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders